Cells Sharing: Transporting Cytoplasmic Contents and Organelles Between Living Cells

A groundbreaking technological advance in cellular engineering has emerged from a team of scientists at Waseda University, Tokyo, led by Professor Takeo Miyake. Their pioneering development introduces a nanotube membrane-based injector capable of sophisticated cytoplasmic transfer, reshaping the landscape of cell manipulation and therapy. This novel platform represents a transformative leap beyond traditional gene editing by enabling the direct, controlled, and efficient transfer of cytoplasmic contents between live cells without compromising viability, promising to revolutionize biomedical research, regenerative medicine, and drug development.

Cells thrive not as isolated units but as dynamic entities that constantly exchange biomolecules and organelles with their neighbors. These exchanges shape tissue development, stress responses, and repair mechanisms. For example, in certain cancers, tumor cells hijack mitochondria from surrounding cells, sustaining their metabolic demands and growth. Similar intercellular exchanges are deeply implicated in aging. However, despite the advent of cutting-edge gene editing like CRISPR and various molecular targeting tools, reliably manipulating the cytoplasmic composition of living cells has remained an unprecedented challenge. Current approaches either destroy cells outright during cytoplasm extraction or fail to deliver sizeable biomolecular cargo efficiently.

Prior methods have faced insurmountable obstacles at multiple stages. Traditional extraction approaches rely on chemical lysis, employing detergents or enzymatic digestion, which sacrificially dismantle cellular integrity. Physically disruptive methods, like ultrasound or microfluidic shear, demand fine-tuning lest vital biomolecules be damaged or cells irreparably harmed. On the delivery front, lipid nanoparticles excel only at transferring small molecules; viral vectors are constrained by cargo size, immunogenicity, and high costs; and microinjections, while precise, are technically demanding and impractical for high-throughput applications. No existing method combined the precise control, efficiency, and cell preservation necessary for live cytoplasmic content transfer—until now.

The newly developed platform utilizes a meticulously engineered thin gold membrane studded with vertically aligned nanotubes integrated on a glass tube structure. Each nanotube acts as a microscopic conduit capable of piercing the phospholipid bilayers of intact, living cells gently and precisely. This physical penetration sidesteps the destructive pitfalls of conventional extraction. By regulating the internal air pressure of the glass tube, the system can effectively “aspirate” cytoplasmic contents from donor cells, temporarily hold them within the nanotube network, then release these contents into recipient cells upon repositioning. This process occurs with microliter precision, preserving the physiological environment and cell viability.

Extensive optimization revealed that the diameter and density of the nanotubes, combined with finely tuned applied pressures, were crucial to achieving minimal cellular damage while maximizing transfer efficiency. Trials employing fluorescent markers and quantitative protein assays validated the pressure-dependent transfer of cytoplasmic constituents. Remarkably, under ideal conditions, recipient cell viability consistently stayed near a remarkable 95%, while the transfer efficiency of cytoplasmic material exceeded 90%. These performance metrics set a new standard for cytoplasmic engineering and underscore the platform’s biocompatibility and precision.

One of the most striking demonstrations of the platform’s potential was its ability to transfer intact mitochondria—functional organelles essential for cellular energy metabolism. Employing fluorescent tagging and state-of-the-art confocal microscopy, the researchers observed numerous mitochondria successfully migrating into recipient cells. More importantly, these transferred mitochondria retained functional integrity, as reflected by significantly elevated intracellular ATP levels in recipient cells relative to controls. This functional enhancement signals revolutionary prospects for mitochondrial repair therapies where dysfunctional mitochondria contribute to diseases or cellular aging.

“This technology introduces a paradigm shift in biomedical engineering,” Professor Miyake reflects. “Rather than altering the genome, we reconstruct the intracellular cytoplasmic environment to modulate cell function directly. It opens unprecedented opportunities to manipulate cell physiology without the ethical and regulatory complexities often associated with genetic modifications.” By harnessing nanomaterial design and fluidic control, the platform bridges formidable gaps between molecular precision and practical application.

The implications of this technology resonate widely. In regenerative medicine, where cell transplantation and therapy efficacy often falter due to metabolic decline and functional heterogeneity in cultured cells, this cytoplasmic injector may restore or augment the energetic capacity by directly supplementing or replacing key organelles such as mitochondria. Moreover, this capability enhances cell quality before therapeutic use, improving clinical outcomes while avoiding genome editing’s potential risks.

Beyond therapy, the platform promises advances in disease modeling and drug discovery. By enabling precise cytoplasmic swapping, researchers can create more physiologically relevant models of cellular dysfunction or pathology, investigating complex cellular responses with unparalleled fidelity. Drug screening platforms can also benefit from enhanced robustness and uniformity in cellular responses when their cytoplasmic environments are carefully engineered.

The innovative integration of nanotechnology and fluid physics encapsulated in this gold nanotube membrane injector not only overcomes long-standing technical hurdles but also positions itself as a versatile tool for future bioengineering research. It achieves a delicate balance between invasiveness and effectiveness, merging the microscopic precision of nanomaterials with the macroscopic practicality needed for widespread adoption.

In summary, the Waseda University team has propelled cell engineering into a new frontier. Their nanotube membrane-based injector offers a scalable, reproducible, and cytocompatible strategy for reshaping intracellular composition directly. The technology’s ability to enhance mitochondrial function further elevates its translational potential, signaling a fresh era in cellular manipulation with far-reaching implications across biomedicine, from fundamental research methodologies to transformative therapeutic interventions.

With this breakthrough, the scientific community gains a powerful instrument to interrogate and influence life’s most fundamental unit: the cell itself. As researchers worldwide embrace this platform, accelerated discoveries and innovative therapies may soon emerge, reaffirming the ever-expanding frontiers of science and human health.

News Publication Date: 17-Mar-2026

Web References: https://onlinelibrary.wiley.com/doi/10.1002/smsc.202500598

References: Bingfu Liu, Zhuhang Dai, Bowen Zhang, Kazuhiro Oyama, Chenxi Li, Yukun Chen, Mingyin Cui, and Takeo Miyake. “A Nanotube Injector for Cytoplasmic Transfer and Enhanced Mitochondrial Function,” Small Science, 17 March 2026.